Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-03
2005-05-03
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S422000, C548S517000, C548S526000, C548S562000, C548S563000
Reexamination Certificate
active
06887893
ABSTRACT:
Certain cyclooxygenase-2 inhibitors are useful for the treatment and prevention of tumors and tumor-related disorders and cachexia.
REFERENCES:
patent: 5208018 (1993-05-01), Gough
patent: 5317019 (1994-05-01), Bender et al.
patent: 5344991 (1994-09-01), Reitz et al.
patent: 5380738 (1995-01-01), Norman et al.
patent: 5418254 (1995-05-01), Huang et al.
patent: 5474995 (1995-12-01), Ducharme et al.
patent: 5486534 (1996-01-01), Lee et al.
patent: 5521207 (1996-05-01), Graneto
patent: 5593991 (1997-01-01), Adams et al.
patent: 5616601 (1997-04-01), Khanna et al.
patent: 5620999 (1997-04-01), Weier et al.
patent: 5633272 (1997-05-01), Talley et al.
patent: 5908858 (1999-06-01), Kimura et al.
patent: 5932598 (1999-08-01), Talley et al.
patent: 2180624 (1997-01-01), None
patent: 799823 (1997-10-01), None
patent: 0799823 (1997-10-01), None
patent: WO 9415932 (1994-07-01), None
patent: WO 9427980 (1994-12-01), None
patent: WO 9500501 (1995-01-01), None
patent: WO 9502600 (1995-01-01), None
patent: WO 9511883 (1995-05-01), None
patent: WO 9515316 (1995-06-01), None
patent: WO 9530656 (1995-11-01), None
patent: WO 9603385 (1996-02-01), None
patent: WO 9603387 (1996-02-01), None
patent: WO 9603388 (1996-02-01), None
patent: WO 9625405 (1996-08-01), None
patent: WO 9636617 (1996-11-01), None
patent: WO 9638418 (1996-12-01), None
patent: WO 9713755 (1997-04-01), None
patent: WO 9727181 (1997-07-01), None
patent: WO 9738986 (1997-10-01), None
patent: WO 9816227 (1998-04-01), None
patent: WO 9822101 (1998-05-01), None
patent: WO 9825896 (1998-06-01), None
Mayo Clinic, Acetaminophen, (Print of Web Article from MayoClinic.com), Nov. 22, 2002.*
Ruff et al., Journal of Clinical Investigat., vol. 73, pp. 1483-1486.*
X. Lu et al, “NSAID-Induced Apoptosis in Rous Sarcoma Virus-Transformed Chicken Embryo Fibroblasts is Dependent on v-srv and c-myc and is Inhibited by bcl-2”,Prostaglandins, vol. 54, pp. 549-568 (Aug. 1997).
T. Hla et al, “Role of the Early Response Gene Cyclooxygenase (COX) -2 in Angiogenesis”,Molecular, Cellular, and Clinical Aspects of Angiogenesis, Edited by M.E. Maragoudakis, Plenum Press, Nato ASI Series, Series A: Life Series, vol. 285, pp. 191-198 (1966).
N. Yoshimi et al, “Inhibitory Effect of NS-398, a Selective Cyclooxygenase-2 Inhibitor, on Azoxymethane-induced Aberrant Crypt Foci in Colon Carcinogenesis of F344 Rats”,Jpn. J. Cancer Res., vol. 88, pp. 1044-1051 (Nov. 1997).
N. Rioux et al, “Recovery from 4-(methylInitrosamino) -1-(3-pyridyl) -1-butanone-Induced Immunosuppression in A/J Mice by Treatment With Nonsteroidal Anti-inflammatory Drugs”,J. Natl. Cancer Inst., vol. 89, No. 12, pp. 874-880 (Jun. 1997).
K. K. Wu, “Cyclooxygenase 2 Induction: Molecular mechanism and pathophysiologic roles”,J. Lab. Clin. Med., vol. 128, No. 3, pp. 242-245 (1996).
H. Sheng et al, “Inhibition of Human Colon Cancer Cell Growth by Selective Inhibition of Cyclooxygenase-2”,J. Clin. Invest., vol. 99, No. 9, pp. 2254-2259 (May 1997).
M. Takahashi et al, “Suppression of azoxymethane-induced aberrant crypt focl in rat colon by nimesulide, a selective Inhibitor of cyclooxygenase 2”,J. Cancer Res. Clin. Oncol., vol. 122, pp. 219-222 (1996).
M. L. Parrett et al, “Cyclooxygenase-2 gene expression in human breast cancer”,Int. J. Oncol., vol. 10, pp. 503-507 (1997).
H.A. Lehmann et al, “Meloxicam: A Toxicology Overview”,Inflammopharmacology, vol. 4, pp. 105-123, Kluwer Academic Publishers (1996).
M. Katori, “Solid tumor, plasma exudation arachidonic acid metabolism”,Igaku no Ayumi, vol. 175, No. 8, pp. 527-531 (1995).
G. G. Sheng et al, “A Selective Cyclooxygenase 2 Inhibitor Suppresses the Growth of H-ras-Transformed Rat Intestinal Epithelial Cells”,Gastroenterology, vol. 113, No. 6, pp. 1883-1891 (Dec. 1997).
P. Huang et al, “Cyclooxygenase and 5-lipoxygenase inhibitors for the prevention and treatment of cancer”, Oncologic, Endocrine & Metabolic—Monthly Update,Exp. Opin. Invest. Drugs, vol. 4, No. 3, pp. 243-249 (1995).
D. J. E. Elder et al, “Induction of Apoptotic Cell Death in Human Colorectal Carcinoma Cell Lines by a Cyclooxygenase-2 (COX) -2) -selective Nonsteroidal Anti-Inflammatory Drug: Independence from COX-2 Protein Expression”,Clin. Cancer Res., vol. 3, pp. 1679-1683 (Oct. 1997).
M. Tsujii et al, “COX-2 . . . ”,Chirougaku, vol. 30, No. 12, pp. 1401-1405 (1996).
M. Tsujii et al, Alterations in Cellular Adhesion and Apoptosis in Epithelial Cells Overexpressing Prostaglandin Endoperoxide Synthase 2,Cell, vol. 83, pp. 493-501 (1995).
D. DeWitt et al, “Yes, but Do They Still Get Headaches?”,Cell, vol. 83, pp. 345-348 (1995).
P. K. Lala et al, “Effects of Chronic Indomethacin Therapy on the Development and Progression of Spontaneous Mammary Tumors in C3H/HEJ Mice”,Int. J. Cancer, vol. 73, pp. 371-380 (1997).
B. S. Reddy et al, “Evaluation of Cyclooxygenase-2 Inhibitor for Potential Chemopreventive Properties in Colon Carcinogenesis”,Cancer Res., vol. 56, pp. 4566-4569 (1996).
I. K. Khanna et al, “1, 2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Antiinflammatory Agents”,J. Med. Chem., vol. 40, pp. 1634-1647 (1997).
I. K. Khanna et al, “1, 2-Diarylpyrroles as Potent and Selective Inhibitors of Cyclooxygenase-2”,J. Med. Chem., vol. 40, pp. 1619-1633, (1997).
McCarthy, “Inhibitors of Prostaglandin Synthesis Do Not Improve Food Intake or Body Weight of Tumor-Bearing Rats”,Research in Nursing&Health, 1999, pp. 380-387, vol. 22).
Malmberg, et al., Capsaicin-evoked prostaglandin E2release in spinal cord slices : relative effect of cyclooxygenase inhibitors,Eur. J. Pharmacol., 271, 293-299 (1994).
Ferrari, et al., estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2levels in mouse brain,Eur. J. Pharmacol., 179, 25-34 (1990).
Shaffer, et al., “Attenuation by Acetaminophen of Arachidonic Acid-Induced Coronary Vasodilation and Output of Prostaglandins in the Isolated Rat Heart”,Eur. J. pharmacol., 72, 57-61 (1981).
Mattammal, et al., “Mechanism of Inhibition of Renal Prostaglandin Production by Acetaminophen”,J. Pharmacol. Exp. Ther., 210, 405-409 (1979).
Damas, et al., “Inhibition De L'Action Hypotensive De L'Acide Arachindonique Chez Le Rat”,J. Pharmacol.(Paris), 9, 1, 13-23 (1978).
Zenser, et al., “Effect of Acetaminophen on Prostaglandin E2and Prostaglandin F2aSynthesis in the Renal Inner Medulla of Rat”,Biochim. Biophys. Acta, 542, 486-495 (1978).
Hanai Masaharu
Kanai Saori
Kimura Tomio
Kurakata Shinichi
Frishauf Holtz Goodman & Chick P.C.
Owens, Jr. Howard V.
Sankyo Company Limited
Wilson James O.
LandOfFree
Methods and compositions for treatment and prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treatment and prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment and prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3433562